Immunome reported positive top‑line Phase 3 results for its oral gamma‑secretase inhibitor, which reduced the risk of disease progression or death by 84% versus placebo in patients with progressing desmoid tumors, the company said. The trial hit its primary endpoint and Immunome intends to file an NDA with the U.S. FDA in 2026, according to the release and analyst coverage. Investigators described the effect size as large and clinically meaningful relative to historical controls in this rare, locally aggressive tumor type. The data position Immunome to pursue regulatory approval next year and underscore renewed investor interest in targeted small molecules for rare, treatment‑resistant neoplasms.